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Abstract: An association between connective tissue growth factor (CTGF) gene dimorphism at –945 (CTGF*-945C/G) 
and systemic sclerosis (SSc) has been reported with inconclusive results. We performed this study to determine whether 
such an association exists among Thai patients with SSc. DNA samples were taken from 50 Thai SSc patients (diffuse 
SSc in 39 and limited SSc in 11) and 99 healthy controls for determination of CTGF*-945C/G dimorphism by polymerase 
chain reaction (PCR) using specific oligonucleotide primers. The associations between the genotype frequencies, clinical 
manifestations and auto-antibodies were determined as well. When compared with the controls, SSc patients had no 
significantly higher frequencies of the GG genotype (44.0% vs 39.4%, p = 0.60), G allele (63.0% vs 65.2%, p = 0.80) or G 
phenotype (82.0% vs 90.9%, p = 1.0). There was no association between the presence of the GG genotype and clinical 
manifestations (pulmonary fibrosis, sclerodactyly, digital pitting scars, telangiectasia and pulmonary arterial 
hypertension), or the presence of auto-antibodies (anti-Scl-70, anti-SSA/Ro, and anti-RNP). In conclusion, we found no 
association between CTGF*-945C/G dimorphism and Thai SSc patients. 
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INTRODUCTION 
  Systemic sclerosis (SSc) or scleroderma is an 
autoimmune disease characterized by extensive organ 
fibrosis, vascular damage and immunologic dysfunctions [1]. 
The skin, lung, heart, kidney and gastrointestinal tract are 
affected mainly, resulting in significant mortality and 
morbidity. The pathogenesis of SSc is not understood 
clearly, but genetic, environmental, and immunologic factors 
are shown to be involved [2, 3]. Older age at disease onset, 
male sex, diffused skin type, and cardiac, pulmonary and 
renal involvements are important predictors for poor 
prognosis and survival rates [4, 5]. 
  Connective tissue growth factor (CTGF) is a growth 
factor that is over expressed in almost all human disorders 
associated with tissue fibrosis [6]. It works synergistically 
with TGF- to promote and sustain fibrosis. The role of 
CTGF in tissue fibrosis in SSc has been reviewed recently 
[7, 8]. Although an association between CTGF*-945C/G 
dimorphism (rs6918698) and SSc was documented in some 
studies [9, 10], it has not been confirmed by others [11-13]. 
  We, therefore, performed this study to determine whether 
there is CTGF*-945C/G dimorphism in Thai patients with SSc. 
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MATERIAL AND METHODS 
  The protocol of the study was approved by the Ethic 
Committee of the Faculty of Medicine, Chiang Mai 
University, and the study was performed in conformity with 
the declaration of Helsinki. Both patients and healthy 
controls (HC) gave their written informed consent before 
they entered the study. 
  Fifty Thai SSc patients and 99 HC were enrolled in the 
study. All SSc patients fulfilled the 1980 American College 
of Rheumatology classification criteria for the diagnosis of 
systemic sclerosis [14]. They were classified further as 
having either a limited subtype (limited cutaneous SSc 
[lcSSc]) or diffuse subtype (diffuse cutaneous SSc [dcSSc]) 
according to the extent of skin involvement, as proposed by 
LeRoy  et al. [15]. The HC comprised medical personnel, 
who showed no signs or symptoms suggesting SSc or any 
other connective tissue diseases, and they were not taking 
any regular medications. In patients with SSc, age, sex, 
duration of disease, type of systemic sclerosis (diffuse 
cutaneous SSc [dcSSc] or limited cutanous SSc [lcSSc]), and 
organs involved were recorded. Duration of the disease 
referred to the period after the onset of symptoms other than 
Raynaud’s phenomenon. Pulmonary hypertension (PH) was 
defined as estimated systolic pulmonary artery pressure 
(sPA) > 45 mmHg, determined by echocardiography [16]. 
Pulmonary artery hypertension (PAH) was defined if the 
mean pulmonary artery pressure exceeded > 25 mmHg, the 
pulmonary wedge pressure was < 15 mmHg, and pulmonary 
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catheterization (RHC) [17]. The RHC used in this study was 
performed within 6 months of the echocardiography. 
Pulmonary fibrosis was diagnosed if a chest radiograph 
showed definite bibasilar pulmonary fibrotic lesions, along 
with bilateral basal lung crepitus on chest auscultation. In the 
case of doubtful pulmonary fibrosis on the chest radiograph, 
a high resolution computed tomography (HRCT) of the chest 
was performed to confirm the diagnosis. The clinical 
features and results of the chest radiograph; HRCT of the 
chest, echocardiography, and RHC performed within 6 
months of the study entry (signed informed consent), were 
used for analysis. The blood was collected for the presence 
of autoantibodies and CTGF*-945C/G dimorphism on the 
day of the study entry. 
  The anti-nuclear antibody (ANA) was determined by 
indirect immunofluorescent methods using HEp-2 cells as a 
substrate by Anti-nuclear Antibody (ANA)(FA) [SRL] 
(TFB, Tokyo, Japan). Anti-centromere antibody was 
determined using MESACUP-2 TEST CENP-B (Medical 
and Biological Laboratories, Nagoya, Japan). Antibodies to 
topoisomerase I (anti-Scl70), ribonucleoprotein (RNP), 
Ro/SSA and La/SSB antigens were determined by the 
enzyme link immunosorbant assay (ELISA) using the Anti-
Scl70 Antibody (E) [S], Anti-RNP Antibody (E) [S], Anti 
SSA/Ro Antibody (E) [S], and Anti SSB/La Antibody (E) 
[S] (TFB, Tokyo, Japan) test kit, respectively. 
  CTGF*-945C/G dimorphism was determined by the 
polymerase chain reaction (PCR) assay of Fonseca and 
Lindahl using the specific oligonucleotide primers with 
minor modifications [9]. In brief, CTGFG1(5’-TATATAGG 
CAAGGACAAGGGAC-3’), CTGFC1(5’-TATATAGGCA 
AGGACAAGGGAG-3’) and CTGFP1(5’-CATGCTCTGA 
AGCATCAACAAC-3’) were used for specific primers, and 
CTGFAPC-210(5’-ATGATGTTGACCTTTCCAGGG-3’) and 
CTGFAPC-211(5’-TTCTGTAACTTTTCATCAGTTGC-3’) 
for control primers. PCR was performed under the following 
conditions: initial denaturation for 1 min at 96 
oC, 5 cycles of 
annealing for 45 sec at 70 
oC, extension for 25 sec at 72 
oC 
and denaturation for 30 sec at 96 
oC, 21 cycles of annealing 
for 50 sec at 65 
oC, extension for 30 sec at 72 
oC and 
denaturation for 30 sec at 96 
oC, and 4 cycles of annealing 
for 60 sec at 55 
oC, extension for 90 sec at 72 
oC and 
denaturation for 30 sec at 96 
oC. Then, the PCR products 
were determined by 2% agarose gel electrophoresis. 
STATISTICAL ANALYSIS 
  The SPSS version 16.0 (Chicago, Illinois) program was 
used for statistical analysis. Association analyses of the 
CTGF*-945C/G dimorphism with clinical features and auto-
antibodies were performed with the Fisher’s exact test. A p-
value of less than 0.05 was considered a statistically 
significant difference. 
RESULTS 
  This study included 99 HC (51 females and 48 males) 
with a mean ± SD age of 45.6 ± 15.1 years, and 50 SSc 
patients (45 females and 5 males), with a mean ± SD age of 
48.7 ± 10.3 years. The SSc patients had a significantly 
greater proportion of females than the HC; 90.0% vs 51.5%, 
p = <0.001. Details of the clinical features and serological  
 
findings in the patients with dcSSc and lcSSc are shown in 
Table 1 . Raynaud’s phenomenon was seen in all patients. 
Among the 50 SSc patients, 48 (39 dcSSc and 9 lcSSC) had 
an echocardiograph performed, and 6 (12.5%) were found to 
have sPA > 45 mmHg or PH. Two of these 6 patients had 
RHC performed, and they were found to have a mean 
pulmonary artery pressure of over 25 mmHg. All 6 of these 
patients also had pulmonary fibrosis on the chest radiograph. 
No patients with an echocardiographic sPA < 45 mmHg had 
RHC performed. Of 34 patients (68.0%), 26 (66.7%) with 
dcSSc and 8 (72.7%) with lcSSc had definite pulmonary 
fibrosis on the chest radiograph. Twenty-four (70.6%) of 
these patients had HRCT of the chest performed, which 
confirmed the pulmonary fibrosis (usual interstitial 
pneumonitis – UIP). Among 16 patients with a normal chest 
radiograph, 2 who had HRCT performed were found to be 
normal. Patients with dcSSc had significantly more digital 
pitting scars and presence of anti-Scl70 than those with 
lcSSc. The frequency of anti-RNP antibody was significantly 
higher in lcSSc than in dcSSc (63.6% vs 23.1%, p = 0.024). 
  The genotype frequencies (GFs), allele frequencies (AFs) 
and phenotype frequencies (PFs) of the CTGF*-945C/G 
dimorphism in Thai patients with SSc and HC are shown in 
Table 2. There was no difference in GFs, AFs and PFs of 
CTGF*-945C/G dimorphism between SSc patients and HC. 
In patients with SSc, there was no significant difference 
between GF of GG (44.0% vs 39.4%, p = 0.60 ), AF of G 
(63.0% vs 65.2%, p = 0.80 ), or PF of G (82.0% vs 90.9%, p 
= 1.0) when compared with the HC. When the frequencies in 
dcSSc and lcSSc were compared to those in the HC, there 
also was no significant difference in GFs, AFs, or PFs of 
CTGF*-945C/G dimorphism. Furthermore, there was no 
association of the CTGF*-945C/G alleles with any SSc 
clinical manifestations or the presence of auto-antibodies. 
Association of the CTGF*-945C/G dimorphism and 
presence of anti-La/SSB and anti-centromere antibodies was 
not performed, due to the small number of cases. 
  As the female sex was disproportionate among SSc 
patients and the HC; the GFs, AFs and PFs of CTGF*-
945C/G dimorphism of the female SSc patients (n = 45) 
were compared to female HC (n = 51), and no significant 
difference was identified (data not shown). The same result 
was found when only females with dcSSc (n=34) were 
compared to those with lcSSc (n = 11), or between male HC 
(n=48) and female HC (n=51) (data not shown). 
DISCUSSION 
  CTGF is a small cysteine-rich matricellular protein which 
is expressed in response to growth factors and other stimuli 
including hypoxia and shear stress [18]. The association of 
CTGF with tissue fibrosis has led to the investigation of 
possible abnormality in the CTGF gene, and the 
development of SSc. The first human genetic study was 
performed by Fonseca et al., who found that the dimorphism 
at the CTGF*-945C/G promoter region was associated with 
SSc [9]. In their study, where most of the patients were white 
UK population, they found that the GF of GG was 
significantly higher in SSc patients than in their controls 
(30.4%  vs 19.2%, p <0.001, OR = 2.2, 95% CI 1.5-3.2). 
They also found that the GG genotype was associated with  
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Table 1.  Clinical and Laboratory Characteristics of Systemic Sclerosis (SSc) Patients 
 
  All dcSSc  lcSSc  p  Value 
N   50   39  11   
Sex, F:M   45:5  34:5  11:0  0.079 
Mean ± SD age, years  48.7 ± 10.3  50.1±10.4  43.9±8.6  0.573 
Mean ± SD duration of disease, years 
- duration from onset 
- duration from Dx 
 
7.1±4.4 
5.8±4.4 
 
6.8±4.6 
5.6±4.6 
 
8.1±4.0 
6.8±3.6 
 
0.408 
0.429 
Telangiectasia (%)  14  15.4  9.1  1.0 
Pulmonary fibrosis (%)  68  66.7  72.7  1.0 
Poikiloderma (%)  50  56.4  27.3  0.171 
Pulmonary hypertension
a (%)  12.5 12.8  1.1 0.578 
Sclerodactyly (%)  84  89.7  63.6  0.059 
Digital pitting scar (%)  72  84.6  27.3  0.001 
Dysphagia (%)  38  41.0  27.3  0.498 
Gastroesophageal reflux disease (%)   34  28.2  54.5  0.151 
Myositis (%)  10  7.7  18.2  0.301 
Arthritis (%)  22  17.9  36.4  0.229 
Anti-nuclear antibody (ANA) (%)  100  100  100  1.0 
Anti-Scl70 (%)  68  84.6  9.1  <0.001 
Anti-centromere (%)   2  0  9.1  0.220 
Anti-RNP (%)  32  23.1  63.6  0.024 
Anti-SSA (%)  34  30.8  45.5  0.475 
Anti-SSB (%)  6  5.1  9.1  0.534 
a Echocardiography was not performed in 2 lcSSc patients. 
 
Table  2.  Association of the CTGF*-945C/G Dimorphism in Thai Healthy Controls and SSc Patients with their Clinical 
Manifestations and Laboratory Findings 
 
GF (%)  AF (%)  PF (%) 
  N 
GG CG  CC  G  C  G  C 
HC  99  39 (39.4)  51 (51.5)  9 (9.1)  129 (65.2)  69 (34.8)  90 (90.9)  60 (60.6) 
All SSc  50  22 (44.0)  19 (38.0)  9 (18.0)  63 (63.0)  37 (37.0)  41 (82.0)  28 (56.0) 
dcSSc  39  19 (48.7)  13 (33.3)  7 (17.9)  51 (65.4)  27 (34.6)  32 (82.1)  20 (51.3) 
lcSSc  11  3 (27.3)  6 (54.5)  2 (18.0)  12 (54.5)  10 (45.5)  9 (81.8)  8 (72.7) 
Sclerodactyly  42  19 (45.2)  16 (38.1)  7 (16.7)  54 (64.3)  30 (35.7)  35 (83.3)  23 (54.8) 
Digital pitting scar   36  13 (36.1)  15 (41.7)  8 (22.2)  41 (56.9)  31 (43.1)  28 (77.8)  23 (63.9) 
Pulmonary fibrosis   34  12 (35.3)  16 (47.1)  6 (17.6)  40 (58.8)  28 (41.2)  28 (82.4)  22 (64.7) 
Telangiectasia  7  4 (57.1)  3 (42.9)  0 (0)  11 (78.6)  3 (21.4)  7 (100)  3 (42.9) 
Pulmonary hypertension   6  1 (16.7)  4 (66.7)  1 (16.7)  6 (50.0)  6 (50.0)  5 (83.3)  5 (83.3) 
Poikiloderma  25  12 (48.0)  10 (40.0)  3 (12.0)  34 (68.0)  16 (32.0)  22 (88.0)  13 (52.0) 
Gastroesophageal reflux disease  17  8 (47.1)  6 (35.3)  3 (17.6)  22 (64.7)  12 (35.3)  9 (52.9)  14 (82.4) 
Dysphagia  19  11 (57.9)  6 (31.6)  2 (10.5)  28 (73.7)  10 (26.3)  17 (89.5)  8 (42.1) 
Myositis  5  2 (40.0)  2 (40.0)  1 (20.0)  6 (60.0)  4 (40.0)  4 (80.0)  3 (60.0) 
Sicca symptoms  5  3 (60.0)  0 (0)  2 (40.0)  6 (60.0)  4 (40.0)  3 (60.0)  2 (40.0) 
Arthritis  11  5 (45.5)  5 (45.5)  1 (9.1)  15 (68.2)  7 (31.8)  10 (90.0)  6 (54.5) 
Anti-Scl70  34  16 (47.1)  13 (38.2)  5 (14.7)  45 (66.2)  23 (33.8)  29 (85.3)  18 (52.9) 
Anti-Ro/SSA  17  4 (23.5)  9 (52.9)  4 (23.5)  17 (50.0)  17 (50.0)  13 (76.5)  13 (76.5) 
Anti-RNP   16  6 (37.5)  8 (50.0)  2 (12.5)  20 (62.5)  12 (37.5)  14 (87.5)  10 (62.5) 
The comparisons were carried out in all frequencies between the SSc group and healthy controls, and between those with the presence or absence of clinical manifestations and auto-
antibodies in the SSc group. No significant difference was found. 62   The Open Rheumatology Journal, 2011, Volume 5  Louthrenoo et al. 
the presence of alveolitis, and anti-Scl-70 and anti-
centromere antibodies. Another study, which supported an 
association between CTGF*-945C/G dimorphism and SSc, 
was carried out by Kawaguchi et al. [10], who performed 
their research in Japanese patients. They found that the GF 
of GG was significantly higher in SSc patients than in 
controls (32.0% vs 22.0%, p = 0.0018). They also found an 
association between the GG genotype with diffused SSc, 
ILD, PAH, and the presence of anti-Scl70 and anti-U1RNP 
antibodies. In contrast, a study performed by Gourh et al. 
[11] in the United States, where most of the patients were 
white North American, African- American and Hispanic 
American (with a ratio of 6.6:1:1.1, respectively), found 
similar GFs of GG among SSc patients and controls (29.0% 
vs 29.8%, p = 0.83, OR = 1.02, 95% CI 0.9-1.2). No 
association with disease subtypes or the presence of anti-Scl-
70, anti-centromere, or anti-RNA polymerase III was 
identified. A multicenter study in 7 populations (6 in Europe 
and 1 in North America) by Rueda et al. [12] also failed to 
confirm this association. Both SSc patients and the controls 
had similar GFs of GG (24.4-29.9% in SSc and 26.6-33.7% 
in controls). Lastly, a recent study in France by Granel et al. 
[13], who performed 7 SNPs on the CTGF gene, could not 
confirm that CTGF*-945C/G SNP was associated with SSc. 
However, they found that the female sex was a risk factor for 
the development of SSc, and the presence of the rs9399005 
T/T SNP was found to be a protective factor for SSc, 
particularly the limited subtype. The discrepancy in results 
might be due mainly to the studies being performed in 
different ethnic groups. Details of previous studies on 
CTGF*-945C/G dimorphism in patients with SSc are 
summarized in Table 3. 
  In this study, we found that the GF of GG in our SSc 
patients (44.0%) was almost equal to that seen in our 
controls (39.4%). In all previous studies, the GF of GG 
ranged from 24.4% to 32.0% in SSc, no matter whether an 
association was found with SSc or not [9-13]. The GF of GG 
in controls was similar to that with disease in studies which 
could not confirm this association, but it was significantly 
lower in studies that showed an association. We could not 
find a significant difference in GFs, AFs, or PFs between 
dcSSc and lcSSc patients, female SSc patients and female 
HC, or female dcSSc and female lcSSc patients. No 
significant association was found between the CTGF*-
945C/G dimorphism and any clinical manifestations or the 
presence of auto-antibodies. 
  One might raise the question of why only 84% of our SSc 
patients had sclerodactyle (89.7 % in dcSSc, and 63.6% in 
lcSSc). The answer might be because this was a cross-
sectional study, and many patients had had a long standing 
disease (mean duration 7 years). Many of these patients had 
turned into the regression phase, when the skin became soft. 
At this stage, the skin over dorsum of their hands was soft, 
and sclerodactyle was not present. The high prevalence of 
anti-Scl70 in dcSSc patients was not unexpected, as almost 
80% of our patients had dcSS. It should be noted that 
approximately two thirds of our patients had pulmonary 
fibrosis, in both the dcSSc and lsSSc group. All of the PH 
patients also had pulmonary fibrosis, indicating that PH in 
our patients was usually secondary to lung disease. 
Therefore, PAH as a result of primary vasculopathy was rare 
in our SSc population. 
  There were some limitations in this study. Firstly, the 
number of patients was quite small. However, SSc is an 
uncommon disease in Thailand; therefore, the small sample 
size in a genetic study might not have too much impact on 
the statistical analysis. Secondly, there was significant 
disproportion of the female sex between SSc patients and the 
HC. However, in re-analysis using only the female SSc 
patients and female HC, no significant difference was found 
in GFs, AFs or PFs between the two groups, indicating that 
the female sex had no effect on genetic analysis of CTGF 
dimorphism. Thirdly, the diagnosis of PH was made by 
echocardiography (sPA > 45 mmHg). This value gave a 97% 
specificity and 98% positive predictive value for pulmonary 
hypertension. However, as most of our cases with PH had 
pulmonary fibrosis on the radiograph (approximately two 
thirds of the cases, in both dcSSc and lcSSc); therefore, PH 
in our SSc patients was likely to be secondary to lung 
disease [19], rather than primary to vasculopathy, as seen in 
idiopathic PAH. 
  In conclusion, we could not confirm the presence of 
CTGF*-945C/G dimorphism in Thai SSc patients. 
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Table 3.  Summary of Studies on CTGF*-945C/G Dimorphism in Patients with SSc 
 
% GG Frequency 
Author (Year)  Country (Ethnicity)  N (Healthy Control, SSc) 
Healthy Control  SSc 
p Value  
Fonseca (2007)   United Kingdom (Caucasian)  1,000 (500, 500)  19.2  30.4  < 0.001 
Gourh (2008)  North America (Caucasian, African-American, Hispanic-American)  1,662 (668, 994)  29.8  29.0  0.83 
Kawaguchi (2009)  Japan (Japanese)  664 (269, 395)  22  32  0.002 
Rueda (2009)  European ancestry (Multi-national)  4,211 (98-317, 98-369)  24.4-29.9  26.6-33.7  0.11-0.75 
Granel (2010)   France (Caucasian)  510 (269, 241)  30.9  22.8  0.61 
Present study  Thailand (Thai)  149 (99, 50)  44.0  39.4  0.60 Lack of CTGF*-945C/G Dimorphism in Thai Patients with Systemic Sclerosis  The Open Rheumatology Journal, 2011, Volume 5   63 
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